Philadelphia CyberKnife Now Accepting Metastatic Cancer Patients in a National Phase I Clinical Trial

Philadelphia CyberKnife recently participated with NRG Oncology in the NRG-BR001 protocol, a Phase I Study of Stereotactic Body Radiotherapy for the Treatment of Multiple Metastases, and successfully completed their first patient treatment in May 2015.

NRG Oncology is a non-profit research organization formed to conduct oncologic clinical research and to broadly disseminate study results for informing clinical decision making and healthcare policy.  The organization seeks to improve the lives of cancer patients by conducting practice-changing multi-institutional clinical and translational research with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers and on localized or locally advanced cancers of all types. 

Most common seen metastatic treatment sites irradiated with ablative radiation therapy are:  brain, lung, liver, adrenal, spine and bone, with the cancer originating from colorectal cancer, non-small lung cancer, breast, prostate, renal cell carcinoma, melanoma and sarcoma.  For certain treatment sites, several retrospective studies have shown positive outcomes of a longer survival and acceptable toxicity with radiosurgery.

The NRG study sought to determine the safety and tolerability of SBRT to treat patients with multiple metastases originating from breast, prostate, and non-small lung cancer, with the primary objective being to define the recommended SBRT dose for each of the metastatic locations being treated.

For more information about the study, please click here.

NRG-BR001 is the latest study from Philadelphia CyberKnife, which has carved a niche for trailblazing clinical research focused on stereotactic body radiation therapy.  CyberKnife® is a robotic technology that provides stereotactic body radiation therapy, a noninvasive method of treating tumors with very precise, high-dose radiation beams in five or fewer procedures.

Contact Philadelphia CyberKnife today at (610) 446-6850 to find out if CyberKnife can be integrated into your treatment plan.

 

This is not intended as medical advice to replace the expertise and judgment of your health care team. It is intended to help you and your family make informed decisions, together with your doctor.